Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules
Neurocrine Biosciences presented real-world data at the American Psychiatric Association 2026 Annual Meeting showing that INGREZZA significantly improves functional outcomes in patients with mild tardive dyskinesia. In a survey of 90 patients with mild TD, 96% showed clinician-reported improvement in uncontrolled movements, with 86% improving within four weeks of treatment initiation.
Key figures
- Drug Name
- INGREZZA (valbenazine)
- Clinicians reporting
- 128
- Patients with mild td
- 90
- Total patients in survey
- 315
- Improvement within 4 weeks pct
- 86
- Improvement in independence pct
- 83
- Independence impact pre treatment pct
- 84
- Improvement in work school ability pct
- 70
- Improvement in uncontrolled movements pct
- 96
- Functional status impact pre treatment pct
- 90
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.